The list of national projects SAS

Back to the list of institutes

Institute: Centre of Experimental Medicine SAS

Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.
Program: Inter-academic agreement
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2018 - 31.12.2020

Catalysing transcriptomic research in cardiovascular disease
Katalýza transkriptomického výskumu kardiovaskulárnych ochorení
Program: COST
Project leader: doc. RNDr. Barteková Monika PhD.
Annotation:This Action aims to create an interdisciplinary network to accelerate the understanding of transcriptomics in cardiovascular disease (CVD) and further the translation of experimental data into usable applications to improve personalized medicine in this field. CVD remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. Currently, there is no network to address the complexity of transcriptomics in CVD, offering an advantage to this Action. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic. This Action will generate grant proposals to advance understanding of the transcriptome’s role in CVD and to translate findings into clinical applications, thus fostering personalized medicine and meeting a current public health challenge. CardioRNA will refine guidelines for transcriptomics investigations in CVD to increase reproducibility of results, facilitating clinical product development. It will disseminate knowledge and allow capacity-building through different types of meetings, prioritizing students and early career investigators. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects and consolidate the leadership of European research groups in the field.
Duration: 3.10.2018 - 2.10.2022

Molecular logic lab-on-a-vesicle for intracellular diagnostics
Molecular logic lab-on-a-vesicle for intracellular diagnostics
Program: Horizon 2020
Project leader: RNDr. Mach Mojmír PhD.
Annotation:A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively. The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far. LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics. With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.
Duration: 1.11.2018 - 31.10.2022

Realising the therapeutic potential of novel cardioprotective therapies
Realizácia terapeutického potenciálu nových kardioprotektívnych terapií
Program: COST
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:The proposed COST Action will set up a pan-European Research Network of leading experts in cardioprotection, to jointly develop new initiatives and new strategies for finding innovative and more effective approaches to cardioprotection and for optimizing the pre-clinical and clinical evaluation of new cardioprotective therapies, so as to improve their translation into the clinical setting for patient benefit. The COST Action will co-ordinate and strengthen European research in the field of cardioprotection and accelerate scientific progress through the dissemination and sharing of new therapeutic targets, among network members and industrial partners, thereby facilitating the discovery of new cardioprotective therapies. By utilizing the joint expertise of different European network members we will investigate factors which confound the efficacy of new cardioprotection therapies including comorbidities (such as age, diabetes, and hypertension) and co-medications (such as anti-platelet therapies, statins and beta-blockers). Finally, we will set up a European network of research centers for multi-center laboratory testing of new cardioprotective therapies using small and large animal models of acute IRI in order to select those therapies most likely to succeed in the clinical setting. All aspects of this COST Action proposal require a critical mass of partners across a wide geographic distribution across Europe in order to deliver the objectives outlined in this proposal. The discovery of novel signaling pathways and targets underlying cardioprotection both within and outside the cardiomyocyte (WG1 NEW TARGETS), and the testing of different combinations of cardioprotective therapy (WG2 COMBINATION THERAPY) requires investigators with different experience and expertise across Europe. The ability to test the effect of confounders of cardioprotection (WG3 CONFOUNDERS) requires the expertise of different partners in the different co-morbidities and testing of co-medications. Finally, the most important objective of this COST Action proposal, requires the setting up of a Europe-wide research network for (a) multicenter testing of novel cardioprotective therapies using small and large animal models (WG4 CONSORTIUM) and (b) testing of novel cardioprotective therapies in proof-of-concept clinical studies and optimization of multi-center clinical outcome cardioprotection studies. By definition this requires a critical mass of research partners distributed across Europe.
Duration: 19.10.2017 - 18.10.2021

Investigation of the mechanims involved in antiarrhythmic effects of melatonin
Skúmanie mechanizmov antiarytmických účinkov melatonínu.
Program: Bilateral - other
Project leader: RNDr. Tribulová Narcisa DrSc.
Annotation:Cardiovascular diseases (CVD) are worldwide major cause of morbidity and mortality due to heart failure and incidence of malignant arrhythmias. Main risk factors of CVD are hypertension, diabetes, dyslipidemia, obesity, chronodisruption and stress. Aimed to prevent CVD and life-threatening arrhythmias it seems extremely important to investigate “pleiotropic” effects of endogenous candidate relevant to the CVD, i.e. neurohormone, melatonin. Neuro-humoral circadian rhythms are ‘chronically’ impaired and result in dys-synchrony of cellular cross talk in different tissues of individuals suffering from CVD. Lack of melatonin was repeatedly reported in patients with coronary heart disease. It appears that melatonin may serve as a new biomarker for a CVD risk. Melatonin in addition to its chrono-regulatory role exerts various “pleiotropic” actions: modulation of blood pressure and NO bioavailability, antioxidant, free radicals scavenging and anti-inflammatory effects, sympatholytic and anti-fibrotic potential and epigenetic regulatory function. Of note, previous experimental studies at both institutions showed clear-cut antiarrhythmic effect of melatonin in various pathophysiological conditions. Findings revealed that melatonin up-regulates myocardial connexin-43 (Cx43), protein of intercellular gap junction channels that are important for electrical impulse propagation and synchronization. Besides, melatonin modulates action potential duration suggesting its effect most likely on potassium and/or calcium channels. Nevertheless, there is a need to elucidate more in details the cellular and molecular mechanisms implicated in antiarrhythmic actions of melatonin
Duration: 1.5.2014 - 31.12.2020

Study of the triggering mechanisms and transmission of cardioprotective signals induced by noninvasive adaptive stimuli
Śtúdium mechanizmov spúšťania a prenosu kardioprotektívných signálov indukovaných neinvazívnymi adaptačnými stimulmi
Program: Inter-academic agreement
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:Cardiovascular diseases are one of the leading causes of mortality in modern society and predicted to rise over the coming decades, due to aging population, longer survival after myocardial infarction, and incidence of civilization diseases. Research pointed out to the protective effects of phenomenon termed ischemic preconditioning (IPC), especially its novel clinically acceptable and safer forms. Currently, cellular mechanisms activated by stimuli like exercise, hypoxia and PC of the remote organ are not yet completely clear as compared with the classiccal IPC. For that reason, pathological animal models (myocardial ischemia, hypertension, d. mellitus, dyslipidemia) and aged animals will be used. Acute PC-like settings of above mentioned interventions, and their longer lasting adaptation modalities will be tested in the in vivo and the ex vivo rats using relevant methodology (combination of physiological, pharmacological and biochemical techniques). The results obtained in this project may lead to development of novel or modified therapeutic strategies to manage myocardial ischemia in patients.
Duration: 1.1.2018 - 31.12.2020

Study the role of iron oxide nanoparticles in a model of hypertension and comorbid Alzheimer's disease
Study the role of iron oxide nanoparticles in a model of hypertension and comorbid Alzheimer's disease
Program: Inter-academic agreement
Project leader: RNDr. Bernátová Iveta DrSc.
Annotation:Slovak partner of this project is focused on investigations of the influence of the biocompatible ultra-small superparamagnetic iron oxide nanoparticles (USPIONs), which are suitable for clinical applications, on function and structure of the arterial wall and the heart in rats with high blood pressure. Bulgarian partner is focused on the role of USPIONs on development of Alzheimer´s disease in a comorbid hypertension. The aim is to investigate if chronic high blood pressure can facilitate the USPIONs uptake in the arterial wall, heart and brain and thus to modify cardiovascular function (including blood pressure regulation) and to induce metabolic disorders. We will determine oxidative and nitrosative damage, inflammatory markers, including proinflammatory cytokines and TNF-alpha in the vasculature, heart, hippocampus and the frontal cortex of normotensive, hypertensive and streptozotocin-treated spontaneously hypertensive rats, a model of comorbid hypertension and Alzheimer´s disease.
Duration: 1.1.2018 - 31.12.2020

Multi-target paradigm for innovative ligand identification in the drug discovery process
Viac-cieľový model pre inovatívnu identifikáciu látok v procese objavovania liečiv
Program: COST
Project leader: RNDr. Májeková Magdaléna PhD.
Annotation:The aim of this COST Action is to join highly-qualified research teams working in disciplines around the field of medicinal chemistry, into a novel network devoted to the multi-target issue in drug discovery. The choice of this theme is related to its marked multidisciplinary character, which can ensure a strong interaction among all COST Action participants. Currently, an important and emerging issue in modern drug discovery is to design novel or identify existing bioactive compounds, endowed with the capability to interact selectively with two or more macromolecular targets, exerting their effects against certain therapeutic goals in a synergic fashion. This leading concept stimulated this COST Action focusing on novel ligands able to recognize selected multiple targets, to promote closer scientific links among European research groups involved in medicinal chemistry field at both academic and industrial level. The research competencies of the network will span around medicinal chemistry, from synthetic chemistry, natural products and biophysics to theoretical chemistry, molecular modelling and biological screening.
Duration: 4.12.2015 - 29.10.2019

The total number of projects: 8